arrow
N

Nathan Morris

Eli Lilly and Company
H指数:24
被引数:3,791

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effects of Mirikizumab versus Placebo on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized, Controlled Phase 3 Trial of Participants With Crohn's Disease
2024-10-010
PRE
Effects of Mirikizumab and Ustekinumab on Histologic Inflammation Evaluated by Comprehensive Assessment in 5 Intestinal Segments in a Randomized Controlled Phase 3 Trial of Participants With Crohn's Disease
2024-10-010
PRE
Early Symptomatic Improvement With Mirikizumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 VIVID-1 Study

中重度活动性克罗恩病患者中,使用Mirikizumab诱导治疗早期症状改善:来自III期VIVID-1研究的结果

2024-10-010
PRE
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies

mirikizumab作为日本中度至重度活动期溃疡性结肠炎患者的诱导和维持治疗的有效性和安全性: 全球3期LUCENT-1和LUCENT-2研究的亚组分析

2024-04-303
OAAI